{"id":534786,"date":"2021-09-07T08:05:19","date_gmt":"2021-09-07T12:05:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/"},"modified":"2021-09-07T08:05:19","modified_gmt":"2021-09-07T12:05:19","slug":"poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/","title":{"rendered":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Sept. 7, 2021<\/span> \/PRNewswire\/ —\u00a0Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:<\/p>\n

\n

\n
\n \"Poseida
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n H. C. Wainwright 23rd Annual Global Investment Conference\u00a0
<\/b>Date: On-demand session opens Monday, September 13, 2021<\/span>
Time: 7:00am ET<\/span><\/p>\n

\n Cantor Fitzgerald Global Healthcare Conference
<\/b>Date: Monday, September 27, 2021<\/span>
Time: 8:40am ET<\/span><\/p>\n

Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com<\/a>.\u00a0An archived replay of each webcast will be available for approximately 30 days following each presentation.\u00a0 <\/p>\n

\n About Poseida Therapeutics, Inc.
<\/b>Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER\u2122<\/span> site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com<\/a> and connect with us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements
<\/b>Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida’s technology platforms and product candidates and Poseida’s plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-301369282.html<\/a><\/p>\n

SOURCE Poseida Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences: H. C. Wainwright 23rd Annual Global Investment Conference\u00a0 Date: On-demand session opens Monday, September 13, 2021Time: 7:00am ET Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 27, 2021Time: 8:40am ET Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com.\u00a0An archived replay of each webcast will be available for approximately 30 days following each presentation.\u00a0 About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to … <\/p>\n

Continue reading “Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534786","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPoseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences: H. C. Wainwright 23rd Annual Global Investment Conference\u00a0 Date: On-demand session opens Monday, September 13, 2021Time: 7:00am ET Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 27, 2021Time: 8:40am ET Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com.\u00a0An archived replay of each webcast will be available for approximately 30 days following each presentation.\u00a0 About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to … Continue reading "Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T12:05:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences\",\"datePublished\":\"2021-09-07T12:05:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1023018\\\/Poseida_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/\",\"name\":\"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1023018\\\/Poseida_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-09-07T12:05:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1023018\\\/Poseida_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1023018\\\/Poseida_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences: H. C. Wainwright 23rd Annual Global Investment Conference\u00a0 Date: On-demand session opens Monday, September 13, 2021Time: 7:00am ET Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 27, 2021Time: 8:40am ET Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com.\u00a0An archived replay of each webcast will be available for approximately 30 days following each presentation.\u00a0 About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to … Continue reading \"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T12:05:19+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences","datePublished":"2021-09-07T12:05:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/","name":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg","datePublished":"2021-09-07T12:05:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1023018\/Poseida_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534786"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534786\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}